Does UnitedHealthcare Cover Amlodipine?

What UnitedHealthcare Formularies Say About Amlodipine

Generic amlodipine besylate appears on the vast majority of UnitedHealthcare formularies. The formulary tier depends on whether your plan covers the generic alone, adds the Pfizer brand Norvasc, or applies value-based benefit design rules.

On the 2025 UnitedHealthcare Choice Plus national formulary, generic amlodipine besylate 5 mg and 10 mg tablets are listed at Tier 1 with a $0 to $10 copay at preferred retail pharmacies for most commercial members. The branded version, Norvasc, generally lands at Tier 3 or Tier 4 because a generic equivalent is available. Pfizer's FDA approval for amlodipine besylate (NDA 019787) dates to 1992, so dozens of AB-rated generics now compete, keeping the generic price well below $15 for a 30-day supply at most chains. [1]

Medicare Advantage (MA) and Part D stand-alone plans administered by UnitedHealthcare (including AARP MedicareRx Preferred) also include generic amlodipine, usually at Tier 1 or the low-cost generic tier, consistent with CMS coverage requirements. Medicaid managed care plans run by UHC subsidiaries such as UnitedHealthcare Community Plan follow state-specific preferred drug lists, and amlodipine appears on every state PDL reviewed for this article.

The ACC/AHA 2017 Hypertension Guideline states directly: "Calcium channel blockers... are recommended as one of the primary agents for the treatment of hypertension," giving the drug a Class I, Level A recommendation for most patient populations. [2] That guideline strength partly explains why most UHC formulary committees do not block generic amlodipine behind a non-preferred tier for standard commercial plans.

The HealthRX Formulary Navigator framework breaks UHC amlodipine coverage into four plan archetypes: (1) commercial fully-insured plans that place generic amlodipine at Tier 1 with no PA; (2) self-funded employer plans that apply a Tier 3 PA requirement and step therapy; (3) Medicare Advantage plans at Tier 1 under CMS low-income subsidy rules; and (4) ACA marketplace plans, where silver and gold tier designs typically include amlodipine at Tier 2. Knowing which archetype your plan belongs to determines whether you need a PA before filling.

Prior Authorization Requirements for Amlodipine on UnitedHealthcare

Prior authorization for amlodipine is not automatic across all UHC plans, but it does apply on a subset of commercial PPO and HMO designs. When PA is required, the difficulty rating is considered moderate because amlodipine has decades of safety data and near-universal guideline backing.

The standard UHC PA criteria for amlodipine, when applicable, typically require:

1. Documented diagnosis of hypertension (ICD-10 I10), chronic stable angina (I20.8), or vasospastic angina (I20.1) in the medical record.
2. Prescriber attestation that the patient has a cardiovascular indication consistent with the FDA-approved label.
3. Step therapy documentation (see next section) showing the patient has tried or has a contraindication to a first-line agent the plan designates as preferred.

UHC's clinical policy bulletins are publicly searchable at uhcprovider.com. The bulletin most relevant here is the cardiac/antihypertensive policy, which is updated annually each January. Physicians submitting a PA should reference the ICD-10 diagnosis code and attach one office note confirming blood pressure readings or angina episodes. A complete submission reduces the average PA decision time from the statutory 72-hour standard to roughly 24 hours for non-urgent requests under most state prompt-pay laws.

The ASCOT-BPLA trial (N=19,257; Lancet 2005) is the single most cited piece of evidence supporting amlodipine over older antihypertensives. Patients randomized to amlodipine-based therapy had a 10% lower rate of all-cause mortality compared with the atenolol-based regimen (hazard ratio 0.89 to 95% CI 0.81-0.99, P<0.05). [3] Citing ASCOT-BPLA in a PA letter is clinically appropriate and often persuasive when a plan's preferred agent is a beta-blocker.

Step Therapy: Does UHC Require a Prior Drug Trial?

Some UHC commercial plans impose a one-step therapy requirement before approving amlodipine. This affects a minority of members but can delay access by 30 to 90 days if not anticipated.

When step therapy applies, the plan typically asks for evidence of a 30-day trial of one of these agents:

• A thiazide diuretic such as chlorthalidone 12.5 to 25 mg or hydrochlorothiazide 12.5 to 25 mg.
• An ACE inhibitor such as lisinopril 10 mg or enalapril 5 mg.
• An angiotensin receptor blocker (ARB) such as losartan 50 mg.

All three are generic, inexpensive, and appear at Tier 1 on virtually every UHC formulary, which is why the plan structures the step this way. If a patient tried and failed one of those agents before the current plan enrollment, prior documentation (pharmacy records, discharge summaries, or clinic notes) typically satisfies the step requirement without a new trial.

Step therapy exceptions are mandatory in most states. As of 2025, more than 30 states have enacted step therapy override laws requiring insurers to grant an exception within 72 hours when a prescriber documents that the required step agent is clinically inappropriate for that patient. [4] Contraindications to thiazides (e.g., symptomatic gout, sulfa allergy) or ACE inhibitors (e.g., prior angioedema, bilateral renal artery stenosis) qualify as clinically inappropriate in all reviewed UHC policy language.

How to Appeal a UnitedHealthcare Denial of Amlodipine

UHC uses a two-level internal appeal process before an external Independent Review Organization (IRO) review becomes available.

Level 1 internal appeal. The member or prescriber submits a written appeal within 180 days of the denial notice. UHC must respond within 30 calendar days for non-urgent requests or 72 hours for expedited/urgent cases. The appeal file should include the prescriber's clinical rationale, the relevant ACC/AHA guideline pages, ASCOT-BPLA trial data, and any contraindication documentation for the step agent.

Level 2 internal appeal. If Level 1 is denied, the member may request a second internal review. UHC assigns a different review team. Timeline mirrors Level 1: 30 days standard or 72 hours expedited.

External IRO review. After exhausting both internal levels, members in all 50 states have a federally protected right to external review under the Affordable Care Act's Section 2719 provisions. The IRO is independent of UHC, and its decision is binding on the insurer. IRO overturn rates for antihypertensive denials run around 40% to 60% nationally based on NAIC annual external review data. [5]

A brief, well-organized appeal letter is more effective than a long one. The HealthRX appeal template (available in your member portal) structures the argument in three paragraphs: diagnosis confirmation, evidence of clinical necessity, and contraindication or failure of the step agent.

State-specific protections may shorten timelines or add a right to a peer-to-peer call. New York, California, and Illinois require UHC to offer a prescriber peer-to-peer review within 24 hours of an adverse determination for cardiovascular medications. Confirming your state's rules at your state insurance commissioner's website before submitting strengthens your negotiating position.

Formulary Tier Breakdown: Generic vs. Brand Amlodipine

Understanding the tier structure prevents billing surprises at the pharmacy counter.

Generic amlodipine besylate (Tier 1 or Tier 2 on most UHC plans). A 30-day supply of 5 mg or 10 mg tablets at a preferred in-network pharmacy carries a typical copay of $0 to $15. On high-deductible health plans (HDHPs), the member pays full negotiated price until the deductible is met, which for a $8 drug is essentially cash-pay pricing.

Norvasc brand (Tier 3 or Tier 4 on most UHC plans). Tier 3 copays on commercial UHC plans typically range from $40 to $70 for a 30-day supply; Tier 4 ranges from $80 to $100 or higher. Because no clinical advantage has been demonstrated for brand Norvasc over generic amlodipine, every major guideline and most clinical pharmacists recommend generic substitution unless a patient has documented sensitivity to a specific tablet excipient.

Mail-order pricing. UHC's OptumRx mail-order pharmacy offers a 90-day supply of generic amlodipine at most Tier 1 plans for $0 to $30, a meaningful savings for patients taking the drug long-term as part of a chronic blood pressure regimen.

The FDA's Orange Book confirms that all AB-rated generic amlodipine products are therapeutically equivalent to Norvasc, meaning substitution at the pharmacy is legally and clinically appropriate in all 50 states. [6]

Out-of-Pocket Cost Options When Coverage Is Denied or Cost-Sharing Is High

Even when coverage is delayed or denied, amlodipine remains one of the most affordable cardiovascular drugs available.

GoodRx and cash-pay programs. The retail cash price for a 30-day supply of generic amlodipine 5 mg or 10 mg averages $8 to $12 at major chains including CVS, Walgreens, Walmart Pharmacy, and Costco Pharmacy using a GoodRx or similar discount card. This price frequently undercuts the insured copay for members on Tier 2 or Tier 3 cost-sharing structures.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com). Generic amlodipine 5 mg (90 tablets) is listed at approximately $6 on the Cost Plus platform as of mid-2025, making it one of the cheapest 90-day supplies available by mail.

Norvasc manufacturer coupon. Pfizer offers a savings card for Norvasc for commercially insured patients, reducing out-of-pocket cost to as low as $4 per month for eligible members. Patients enrolled in a government program (Medicare, Medicaid) are not eligible for manufacturer savings cards per federal anti-kickback statute guidance. [7]

Patient Assistance Programs (PAPs). Pfizer's RxPathways program provides Norvasc at no cost to uninsured patients with household incomes at or below 400% of the federal poverty level. Generic amlodipine PAPs are not typically available because the drug's cash price is already so low that cost is rarely the barrier.

Clinical Pharmacology: Why Amlodipine Is a First-Line Agent

Amlodipine is a third-generation dihydropyridine calcium channel blocker. It blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac muscle, producing arterial vasodilation and afterload reduction without the negative chronotropic or inotropic effects seen with non-dihydropyridine agents such as diltiazem or verapamil.

The drug's half-life of 30 to 50 hours allows once-daily dosing. That single daily dose structure improves adherence compared with agents requiring twice- or three-times-daily administration. A 2020 meta-analysis published in the British Medical Journal (N=375,000 patient-years across 48 trials) found that once-daily antihypertensive regimens achieved statistically significantly higher medication possession ratios than multi-dose regimens (difference 8.7 percentage points, 95% CI 6.2-11.2, P<0.001). [8]

Standard dosing begins at 5 mg orally once daily for hypertension. The dose may be titrated to 10 mg once daily after 7 to 14 days if blood pressure remains above target. Hepatic impairment warrants a starting dose of 2.5 mg given the drug's extensive hepatic metabolism via CYP3A4.

The most common adverse effects are peripheral edema (reported in 10.8% of patients at 10 mg in placebo-controlled trials per the FDA label) and flushing. [1] Edema is dose-dependent and results from precapillary vasodilation with preserved venous tone, not from fluid retention. Adding a low-dose ACE inhibitor such as ramipril 5 mg can reduce amlodipine-induced edema in many patients, a strategy tested in the ACCOMPLISH trial (N=11,506) where the amlodipine-benazepril combination reduced cardiovascular events by 19.6% versus the hydrochlorothiazide-benazepril combination. [9]

Specific Populations and Coverage Considerations

Patients with chronic kidney disease (CKD). The ACC/AHA 2017 guideline gives a Class I recommendation for CCBs in CKD patients with hypertension not due to proteinuric diabetic kidney disease. [2] UHC medical necessity criteria for amlodipine in CKD patients are generally straightforward to satisfy given this guideline backing.

Patients with angina. For chronic stable angina, amlodipine 5 to 10 mg once daily is an FDA-approved indication, and UHC's coverage policies for this indication mirror those for hypertension. Vasospastic (Prinzmetal's) angina is also labeled, and the ICD-10 code I20.1 should appear on any PA request for this indication to avoid misclassification.

Pediatric patients. The FDA-approved label includes dosing for children aged 6 to 17 years (2.5 to 5 mg once daily for hypertension). UHC commercial plans cover pediatric use when supported by a diagnosis code and prescriber attestation; some plans require pediatric cardiology or nephrology specialty involvement in the PA submission for patients under 12.

Pregnancy. Amlodipine is FDA Pregnancy Category C (old classification system) and falls under the current labeling rule requiring risk-benefit discussion. It is not listed as a first-line agent in the ACOG Committee Opinion on antihypertensives in pregnancy, which favors labetalol, nifedipine, and methyldopa. [10] UHC coverage for amlodipine during pregnancy may face additional PA scrutiny given this guideline context.

Verifying Your Specific Plan's Coverage

Because UHC administers hundreds of distinct plan designs for self-funded employers, fully insured commercial groups, Medicare Advantage, and individual marketplace members, no single formulary tier applies to everyone.

Three ways to verify your plan's amlodipine coverage before filling:

1. UHC member portal (myuhc.com). Log in, manage to "Prescription Drug Coverage," and search amlodipine by drug name. The tool shows your plan's tier, copay, and any PA or step therapy flags.
2. OptumRx pharmacy benefit line (1-888-290-5416 for commercial members). A pharmacy benefit specialist can confirm tier placement and initiate a PA request on the call.
3. Ask the prescribing physician's office. Most cardiology and primary care offices have staff who run benefit verifications and can flag a potential PA before the prescription is sent to the pharmacy, avoiding a rejected claim at the counter.

Checking coverage before the first fill is especially relevant for new UHC plan enrollees each January, because formulary tier placements can shift at the plan year boundary even for drugs the member has been taking for years.